國家衛生研究院 NHRI:Item 3990099045/12231
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 858808      線上人數 : 798
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    主頁登入上傳說明關於NHRI管理 到手機版
    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/12231


    題名: Anti-inflammatory compound shows therapeutic safety and efficacy against flavivirus infection
    作者: Chuang, FK;Huang, SM;Liao, CL;Lee, AR;Lien, SP;Chiu, YL;Chang, TH;Tsai, PL;Lin, RJ;Shih, CC;Tsai, YJ;Lin, GJ;Yen, LC
    貢獻者: National Institute of Infectious Diseases and Vaccinology;National Mosquito-Borne Diseases Control Research Center
    摘要: Flaviviruses comprise several medically important viruses, including Japanese encephalitis virus, West Nile virus, dengue virus (DENV), yellow fever virus and Zika virus (ZIKV). A large outbreak of DENV and ZIKV occurred recently, leading to many cases of illness and death. However, despite decades of efforts, we have no clinically specific therapeutic drugs against DENV and ZIKV. Previous studies showed that inflammatory responses play a critical role in dengue and Zika pathogenesis. Thus, in this study, we examined a series of novel anti-inflammatory compounds and found that treatment with compound 2d could dose-dependently reduce viral protein expression and viral progeny production in HEK-293 and Raw264.7 cells with four serotypes of DENV and ZIKV infection. As well, considering medication safety, compound 2d could not suppress cyclooxygenase-1 (COX-1) enzymatic activities and thus could prevent bleeding side effect. Moreover, compound 2d significantly inhibited COX-2 enzymatic activities and prostaglandin E2 levels, associated with viral replication, as compared with a selective COX-2 inhibitor, celecoxib. Furthermore, administering 5 mg/kg compound 2d to DENV-2-infected AG129 mice prolonged survival and reduced viremia and serum cytokine levels. Overall, compound 2d showed therapeutic safety and efficacy in vitro and in vivo and could be further developed as a potential therapeutic agent for flavivirus infection.
    日期: 2020-01
    關聯: Antimicrobial Agents and Chemotherapy. 2020 Jan;64(1):Article number e00941-19.
    Link to: http://dx.doi.org/10.1128/aac.00941-19
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0066-4804&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000503839600007
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85077016896
    顯示於類別:[廖經倫] 期刊論文
    [其他] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB31636070.pdf2379KbAdobe PDF254檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋